Ticker
ACAD

Price
19.83
Stock movement down
-0.08 (-0.40%)
Company name
ACADIA Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
3.21B
Ent value
3.23B
Price/Sales
6.28
Price/Book
7.54
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-15.29%
3 year return
-21.93%
5 year return
-8.11%
10 year return
12.42%
Last updated: 2023-02-03

DIVIDENDS

ACAD does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales6.28
Price to Book7.54
EV to Sales6.32

FINANCIALS

Per share

Loading...
Per share data
Current share count161.93M
EPS (TTM)-1.34
FCF per share (TTM)-0.70

Income statement

Loading...
Income statement data
Revenue (TTM)511.50M
Gross profit (TTM)501.19M
Operating income (TTM)-222.19M
Net income (TTM)-217.34M
EPS (TTM)-1.34
EPS (1y forward)-0.78

Margins

Loading...
Margins data
Gross margin (TTM)97.98%
Operating margin (TTM)-43.44%
Profit margin (TTM)-42.49%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash154.84M
Net receivables56.14M
Total current assets521.55M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets602.49M
Accounts payable10.01M
Short/Current long term debt63.00M
Total current liabilities116.57M
Total liabilities176.81M
Shareholder's equity425.69M
Net tangible assets425.69M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-113.30M
Capital expenditures (TTM)1.00K
Free cash flow (TTM)-113.30M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-51.06%
Return on Assets-36.07%
Return on Invested Capital-49.97%
Cash Return on Invested Capital-26.05%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open19.54
Daily high20.11
Daily low19.53
Daily Volume1.21M
All-time high57.00
1y analyst estimate18.47
Beta0.59
EPS (TTM)-1.34
Dividend per share-
Ex-div date-
Next earnings date27 Feb 2023

Downside potential

Loading...
Downside potential data
ACADS&P500
Current price drop from All-time high-65.21%-13.68%
Highest price drop-96.29%-56.47%
Date of highest drop12 Nov 20109 Mar 2009
Avg drop from high-47.92%-11.49%
Avg time to new high51 days13 days
Max time to new high1820 days1805 days
COMPANY DETAILS
ACAD (ACADIA Pharmaceuticals Inc) company logo
Marketcap
3.21B
Marketcap category
Mid-cap
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Employees
510
Investor relations
-
SEC filings
CEO
Stephen R. Davis
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
SAN DIEGO, January 09, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. ...
January 9, 2023
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
January 3, 2023
SAN DIEGO, January 03, 2023--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in p...
January 3, 2023
Acadia Pharmaceuticals is working to develop novel RNA-based medicines for the treatment of severe and rare genetic diseases of the central nervous system. The On-Balance-Volume (OBV) line has weake...
January 3, 2023
SAN DIEGO, December 21, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00...
December 21, 2022
SAN DIEGO, November 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
November 8, 2022
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
November 3, 2022
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 2, 2022
SAN DIEGO, November 02, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
November 2, 2022
Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
November 1, 2022
Next page